Detralex, 1000 mg 30 pcs

Detralex has venotonic and angioprotective properties. The drug reduces venous distensibility and venous stasis, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug with respect to indexes of venous hemodynamics.

A statistically significant dose-dependent effect of the drug Detralex has been demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, and venous emptying time.

The optimal dose-effect ratio is observed when taken at a dose of 1000 mg per day.

Detralex increases venous tone: venous occlusion plethysmography has been shown to decrease time of venous emptying. In patients with signs of severe microcirculatory disorders after therapy with Detralex an increase of capillary resistance evaluated by angiostereometry was noted (statistically significant compared to placebo).

Therapeutic effectiveness of the drug Detralex in the treatment of chronic diseases of the lower limbs veins and in the treatment of hemorrhoids has been proved.

Indications

Detralex is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).

Treatment of symptoms of venous-lymphatic insufficiency:
pain;
spasms of the lower extremities;
feeling of heaviness and fullness in the legs;
“tired” legs.
Treatment of manifestations of venous-lymphatic insufficiency:
swelling of the lower extremities;
trophic changes in the skin and subcutaneous tissue;
venous trophic ulcers.
Symptomatic treatment of acute and chronic hemorrhoids.

Pharmacological effect

Detralex has venotonic and angioprotective properties. The drug reduces the distensibility of veins and venous stagnation, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to indicators of venous hemodynamics.

A statistically significant dose-dependent effect of the drug Detralex was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time.

The optimal dose-effect ratio is observed when taken at a dose of 1000 mg per day.

Detralex increases venous tone: using venous occlusion plethysmography, a decrease in the time of venous emptying was shown. In patients with signs of severe microcirculation disorders, after treatment with Detralex there is a (statistically significant, compared to placebo) increase in capillary resistance, assessed by angiostereometry.

The therapeutic effectiveness of the drug Detralex has been proven in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.

Special instructions

Before starting to use the drug Detralex®, the patient is recommended to consult a doctor.

In case of exacerbation of hemorrhoids, the prescription of Detralex® does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the “Dosage regimen” section. If the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist who will select further therapy.

In the presence of venous circulation disorders, the maximum effect of treatment is ensured by combining therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, long periods of standing, and it is also recommended to reduce excess body weight. Walking and, in some cases, wearing special stockings helps improve blood circulation.

The patient should immediately consult a doctor if the condition worsens or does not improve during treatment.

The drug does not affect the ability to drive vehicles or perform work that requires high speed mental and physical reactions.

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

1 tablet contains purified micronized flavonoid fraction 1000 mg, including:

diosmin 900 mg (90%)
flavonoids in terms of hesperidin 100 mg (10%)

30 tablets for oral administration per package

Pregnancy

Pregnancy

There are no or limited data on the use of purified micronized flavonoid fraction in pregnant women.
Animal studies have shown no reproductive toxicity.
As a precautionary measure, it is preferable not to use this product during pregnancy.

Breastfeeding period

It is unknown whether the purified micronized flavonoid fraction (metabolites) passes into human breast milk.
A risk for newborns and infants cannot be excluded. A decision must be made either to stop breastfeeding or to discontinue this medication, taking into account the benefits of breastfeeding for the child and the benefits of therapy for the woman.

Effect on reproductive function

Reproductive toxicity studies showed no effect on reproductive function in rats of either sex.

Contraindications

Hypersensitivity to the active components or excipients included in the drug.
Pregnancy and breastfeeding (limited or no experience with use).
Children under 18 years of age (no experience of use).

Side Effects

Side effects of Detralex® observed during clinical trials were mild. Mostly gastrointestinal disorders were observed (diarrhea, dyspepsia, nausea, vomiting).

While taking the drug Detralex®, the following side effects were reported in the following gradation: very often (≥1/10), often (≥1/100, <1/10), infrequently (≥1/1000, <1/100), rarely (≥1/10,000, <1/1000), very rarely (<10,000), unspecified frequency (frequency cannot be specified) calculated from available data).

From the side of the central nervous system: rarely – dizziness, headache, general malaise.

From the gastrointestinal tract: often – diarrhea, dyspepsia, nausea, vomiting; infrequently – colitis; unspecified frequency – abdominal pain.

From the skin: rarely – rash, itching, urticaria; unspecified frequency – isolated swelling of the face, lips, eyelids; in exceptional cases – angioedema.

The patient should be informed that if any symptoms appear during therapy, incl. Undesirable reactions and sensations not mentioned in the instructions, as well as changes in laboratory parameters, should be reported to your doctor.

Interaction

There were no drug interactions with Detralex®.

The attending physician should be informed about all medications the patient is taking.

Overdose

No cases of overdose have been described.

In case of overdose of the drug, the patient should immediately seek medical help.

Manufacturer

Servier Rus LLC, Russia